APA

Sostelly A., Henin E., Chauvenet L., Hardy-Bessard A., Jestin-Le Tallec V., Kirsher S., Leyronnas C., Ligeza-Poisson C., Ramdane S., Salavt J., Van-Hult S., Vannetzel J., Freyer G., Tod M. & Falandry C. (20140416). Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO. : Journal of geriatric oncology.

Chicago

Sostelly Alexandre, Henin Emilie, Chauvenet Laure, Hardy-Bessard Anne-Claire, Jestin-Le Tallec Véronique, Kirsher Sylvie, Leyronnas Cécile, Ligeza-Poisson Catherine, Ramdane Soraya, Salavt Jacques, Van-Hult Sylvie, Vannetzel Jean-Michel, Freyer Gilles, Tod Michel and Falandry Claire. 20140416. Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO. : Journal of geriatric oncology.

Harvard

Sostelly A., Henin E., Chauvenet L., Hardy-Bessard A., Jestin-Le Tallec V., Kirsher S., Leyronnas C., Ligeza-Poisson C., Ramdane S., Salavt J., Van-Hult S., Vannetzel J., Freyer G., Tod M. and Falandry C. (20140416). Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO. : Journal of geriatric oncology.

MLA

Sostelly Alexandre, Henin Emilie, Chauvenet Laure, Hardy-Bessard Anne-Claire, Jestin-Le Tallec Véronique, Kirsher Sylvie, Leyronnas Cécile, Ligeza-Poisson Catherine, Ramdane Soraya, Salavt Jacques, Van-Hult Sylvie, Vannetzel Jean-Michel, Freyer Gilles, Tod Michel and Falandry Claire. Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO. : Journal of geriatric oncology. 20140416.